1.    Lin Y, Wang B, Shan W, Tan Y, Feng J, Xu L, Wang L, Han B, Zhang M, Yu J, Yu X, Huang H*. mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation. Clin Immunol. 2017 Nov 10. 

2.    Wang J, Hu Y, Huang H*. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. J Leukoc Biol. 2017 Dec;102(6):1347-1356

3.    Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies foradult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol.2017 Aug 18;10(1):150.

4.    Zhao Y, Wang J, Luo Y, Shi J, Zheng W,Tan Y, Cai Z, Huang H*. Reduced-intensityallogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinibtreatment in young patients with chronic myeloid leukemia. Ann Hematol. 2017Aug;96(8):1353-1360.

5.    Liu S, Ye Z, Gao Y, He C, Williams DW, Moliterno A, Spivak J, Huang H*, ChengL.Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. Stem Cell Res. 2017 Jan;18:57-59.

6.    Santoro N, Ruggeri A, Labopin M,Bacigalupo A, Ciceri F, Gülbaş Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y,Tischer J, Santarone S, Giebel S, Mohty M, Nagler A. Unmanipulatedhaploidentical stem cell transplantation in adults with acute lymphoblasticleukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.JHematol Oncol. 2017;10(1):113. 

7.    Yu J, Hu Y, Pu C, Liang Z, Cui Q,Zhang H, Luo Y, Shi J, Jin A, Xiao L, Wu Z, Huang H*.Successfulchimeric Ag receptor modified T cell therapy for isolated testicular relapseafter hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.BoneMarrow Transplant. 2017 Jul;52(7):1065-1067.

8.    Wei G, Ding L, Wang J, Hu Y, Huang H*. Advances of CD19-directed chimericantigen receptor-modified T cells in refractory/relapsed acute lymphoblasticleukemia. Exp Hematol Oncol. 2017 Apr14;6:10. 

9.    Lai R, Gu M, Jiang W, Lin W, Xu P, LiuZ, Huang H, An H, Wang X*.Raf Kinase Inhibitor Protein Preferentially Promotes TLR3-Triggered Signaling and Inflammation. J Immunol.2017 May 15;198(10):4086-4095. 

10.  Tan Y, Xiao H, Wu D, Luo Y, Lan J, LiuQ, Yu K, Shi J, He J, Zheng W, Lai X, Zhu Y, Du K, Ye Y, Zhao Y, Zheng G, Hu Y,Han X, Zheng Y, Wei G, Cai Z, Huang H*. Oncoimmunology. Combining therapeutic antibodiesusing basiliximab and etanercept for severe steroid-refractory acutegraft-versus-host disease: A multi-center prospective study. 2017 Jan6;6(3):e1277307. 

11.  Han B, Zhao Y, Lin Y, Fu S, Wang L,Zhang M, Tie R, Wang B, Luo Y, Liu L, Yu J, Huang H*.Hydroxychloroquine sensitizes chronicmyeloid leukemia cells to Vγ9Vδ2 T cell-mediated lysis independent ofautophagy. Int J Oncol. 2017May;50(5):1810-1820.

12.  Tie R, Zhang T, Yang B, Fu H, Han B,Yu J, Tan Y, Huang H*. Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. Oncotarget.2017 Apr 18;8(16):27645-27660. 

13.  Piemontese S, Ciceri F, Labopin M,Arcese W, Kyrcz-Krzemien S, Santarone S, Huang H, Beelen D, Gorin NC, Craddock C,Gulbas Z, Bacigalupo A, Mohty M, Nagler A. A comparison between allogeneic stemcell transplantation from unmanipulated haploidentical and unrelated donors inacute leukemia.J Hematol Oncol. 2017 Jan 19;10(1):24.

14.  Han X, Wang L, Shi H, Zheng G, He J,Wu W, Shi J, Wei G, Zheng W, Sun J, Huang H, Cai Z*. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathyin patients with multiple myeloma. BMC Cancer. 2017 Jan 9;17(1):40. 

15.  Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C,Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A,Zhang H, Cai Z, Xiao L, Huang H*. Potent Anti-leukemia Activities ofChimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patientswith Relapsed/Refractory Acute Lymphocytic Leukemia. Clin Cancer Res. 2017 Jul1;23(13):3297-3306.

16.  Wang Y, Wang Y, Chang T, Huang H*, Yee JK. Integration-defectivelentiviral vector mediates efficient gene editing through homology-directedrepair in human embryonic stem cells. Nucleic Acids Res. 2017 Mar 17;45(5):e29.

17.  Hu Y, Cui Q, Ye Y, Luo Y, Tan Y, ShiJ,  Huang H*. Reduction ofFoxp3+ T cell subsets involved in incidence of chronic graft-versus-hostdisease after allogeneic hematopoietic stem cell transplantation.HematolOncol.2017 Mar;35(1):118-124. 

18.  Gu M, Liu Z, Lai R, Liu S, Lin W,Ouyang C, Ye S, Huang H, Wang X*. RKIPand TBK1 form a positive feedback loop to promote type I interferon productionin innate immunity. EMBO J. 2016 Dec 1;35(23):2553-2565.

19.  Zhang M, Fu H, Lai X, Tan Y, Zheng W,Shi J, Zhao Y, Lin M, He J, Cai Z, Luo Y, Huang H*. Minimal Residual Disease at FirstAchievement of Complete Remission Predicts Outcome in Adult Patients withPhiladelphia Chromosome-Negative Acute Lymphoblastic Leukemia. PLoS One. 2016Oct 3;11(10):e0163599.

20.  Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL,  Huang H*. Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.Chin Med J (Engl). 2016 Oct 20; 129 (20): 2512-2513. 

21.  Xu Y, Shan W, Li X, Wang B, Liu S,Wang Y, Long Y, Tie R, Wang L, Cai S, Zhang H, Lin Y, Zhang M, Zheng W, Luo Y,Yu X, Yee JK, Ji J, Huang H*. A syntheticthree-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells. J Hematol Oncol.2016 Sep 29;9(1):102.

22.  Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C,Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H*. Predominant cerebral cytokine releasesyndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. JHematol Oncol. 2016 Aug 15;9(1):70. 

23.  Zhu N, Wang H, Wei J, Wang B, Shan W,Lai X, Zhao Y, Yu J, Huang H*. NR2F2regulates bone marrow-derived mesenchymal stem cell-promoted proliferation ofReh cells. Mol Med Rep. 2016 Aug;14(2):1351-6. 

24.  Liu L, Yu Q, Hu K, Wang B, Zhang Y, XuY, Fu S, Yu X, Huang H*. Electro Acupuncture Promotes Endogenous Multipotential Mesenchymal Stem Cell Mobilization into the Peripheral Blood. Cell PhysiolBiochem. 2016;38(4):1605-17.

25.  Luo C, Wang J, Hu Y, Luo Y, Tan Y, JinA, Wei B, Hu H, Huang H*.Cunning hamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review ofthe Literature.Mycopathologia. 2016 Oct;181(9-10):753-8.

26.  Ye Y, Zheng W, Wang J, Hu Y, Luo Y,Tan Y, Shi J, Zhang M, Huang H*. Risk and prognostic factors oftransplantation-associated thrombotic microangiopathy in allogeneichaematopoietic stem cell transplantation: a nested case control study. HematolOncol. 2016 Jun 1. 

27.  Wu WJ, Dong MM, Chen Y, He JS, Huang H, Cai Z*.Acute myeloid leukemia of a primary hepatic carcinoma patient after liver transplantation: a case reportand literature review. Int J Clin Exp Pathol. 2015 .8(10):13655-60.

28.  26. Zhu N, Wang H, Wang B, Wei J, Shan W,Feng J, Huang H*.A Member ofthe Nuclear Receptor Superfamily, Designated as NR2F2, Supports theSelf-Renewal Capacity and Pluripotency of Human Bone Marrow-Derived MesenchymalStem Cells. Stem Cells Int. 2016:5687589. 

29.  Lin W, Ma C, Su F, Jiang Y, Lai R,Zhang T, Sun K, Fan L, Cai Z, Li Z, Huang H, Li J, Wang X*. Raf kinase inhibitorprotein mediates intestinal epithelial cell apoptosis and promotes IBDs inhumans and mice.Gut. 2016 Jan 22. 

30.  Zhou M, Zheng Y, Ma S, Zhou, Li L, ZhuJ, Zhu L, Yang X, Luo Y, Huang H, Ye X, Xie W*. Clinical observationon hemogram variation of allogeneic donors from Chinese population forperipheral hematopoietic stem cells collection.Stem Cells Dev. 2016.25(10):798-802.

31.  Hu Y, Cui Q, Luo C, Luo Y, ShiJ,  Huang H*. A promisings word of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.Blood Rev. 2016.30(3):179-188. 

32.  Xiao H, Wang LM, Luo Y, Lai X, Li C,Shi J, Tan Y, Fu S, Wang Y, Zhu N, He J, Zheng W, Yu X, Cai Z,  Huang H*.  Mutations in epigenetic regulators areinvolved in acute lymphoblastic leukemia relapse following allogeneichematopoietic cell transplantation. Oncotarget. 2016. 7(3):2696-708. 

33.  Long Y,  HuangH*. On signalingpathways: hematopoietic stem cell specification from hemogenic endothelium. SciChina Life Sci. 2015.58(12):1256-61.

34.  Wang L, Xiao H, Zhang X, Liao W, Fu S, Huang H*.  Restoration of CCAAT enhancer binding proteinα P42 induces myeloid differentiation and overcomes all-trans retinoic acidresistance in human acute promyelocytic leukemia NB4-R1 cells. Int J Oncol.2015 Nov;47(5):1685-95.

35.  Zheng FL, Shi JM, Hu YX, Zheng YL, CaiZ, Huang H*. The first casereport of a patient with simultaneous haemophilia A and accelerated phasechronic myelogenous leukaemia. Haemophilia. 2015 Nov;21(6):e507-10.

36.  Shi JM, Pei XY, Luo Y, Tan YM, Tie RX,He JS, Zheng WY, Zhang J, Cai Z, Lin MF,  HuangH*.. Invasivefungal infection in allogeneic hematopoietic stem cell transplant recipients:single center experiences of 12 years.J Zhejiang Univ Sci B. 2015Sep;16(9):796-804. 

37.  Hu K, Gu Y, Lou L, Liu L, Hu Y, WangB, Luo Y, Shi J, Yu X, Huang H*. Galectin-3mediates bone marrow microenvironment-induced drug resistance in acute leukemiacells via Wnt/β-catenin signaling pathway.J Hematol Oncol. 2015 Jan 27;8(1):1. 

38.  Gorin NC, Labopin M, Piemontese S,Arcese W, Santarone S, Huang H, Meloni G,Ferrara F, Beelen D, Sanz M, Bacigalupo A, Ciceri F, Mailhol A, Nagler A, MohtyM. T-cell-replete haploidentical transplantation versus autologous stem celltransplantation in adult acute leukemia: a matched pair analysis. Haematologica.2015 Apr;100(4):558-64.

39.  Zhu N, Xiao H, Wang LM, Fu S, ZhaoC, Huang H*. Mutations intyrosine kinase and tyrosine phosphatase and their relevance to the targettherapy in hematologic malignancies. Future Oncol. 2015 Feb;11(4):659-73. 

40.  Ruggeri A, Labopin M, Sanz G,Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, HuangH, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J,Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E,Ciceri F, Rocha V, Mohty M. Comparison of outcomes after unrelated cord bloodand unmanipulated haploidentical stem cell transplantation in adults with acuteleukemia.Leukemia. 2015.29(9):1891-900.

41.  Wang B, Hu Y, Liu L, Hu K, Tie R, HeY, Fu S, Zhu N, Luo Y, Yu X, Huang H*. Phenotypicaland Functional Characterization of Bone Marrow Mesenchymal Stem Cells inPatients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015.21(6):1020-8. 

42.  Wang X, Wang Y, Wu X, Wang J, Wang Y,Qiu Z, Chang T, Huang H, Lin RJ, YeeJK. Nat Biotechnol. Unbiased detection of off-target cleavage by CRISPR-Cas9and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol. 2015Feb;33(2):175-8.

43.  PiemonteseS, Ciceri F, Labopin M, Bacigalupo A, HuangH, Santarone S, Gorin NC, Koc Y, Wu D, Beelen D, Tischer J, Ehninger G,Arcese W, Nagler A, Mohty M*. A survey on unmanipulated haploidenticalhematopoietic stem cell transplantation in adults with acute leukemia.Leukemia. 2015.29(5):1069-75.

44.  FuS, Wei J, Wang G, Wang B, Wang Y, Lai X, Huang H*. The key role of PML in IFN-α induced cellularsenescence of human mesenchymal stromal cells. Int J Oncol. 2015. 46(1):351-9. 

45.  ZiFM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, Zheng GF,Han XY, Huang H, Yi Q, Cai Z.Metformin displays anti-myeloma activity and synergistic effect withdexamethasone in vitro and in xenograft models. Cancer Lett. 2015. 356(2 PtB):443-53.

46.  ChenB, Chen X, Wu X, Wang X, Wang Y, Lin TY, Kurata J, Wu J, Vonderfecht S, SunG, Huang H, Yee JK, Hu J, Lin RJ. Disruption of microRNA-21 byTALEN leads to diminished cell transformation and increased expression ofcell-environment interaction genes. Cancer Lett. 2015.356(2 Pt B):506-16.

47.  Wang L, Xiao H, Zhang X, Wang C, Huang H*.The role oftelomeres and telomerase in hematologic malignancies and hematopoietic stemcell transplantation. J Hematol Oncol. 2014Aug 20;7:61. 

48.  Gu M, Zhang T, Lin W, Liu Z, Lai R, Xia D, Huang H , Wang X*.Protein phosphatase PP1 negatively regulates the Toll-like receptor- andRIG-I-like receptor-triggered production of type I interferon by inhibitingIRF3 phosphorylation at serines 396 and 385 in macrophage. Cell Signal. 2014.26(12):2930-9. 

49.  Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W,Zhu Y, Ye X, Yu X, Cai Z, Lin M, HuangH*. T-cell-replete haploidentical HSCT with low-doseanti-T-lymphocyte globulin compared with matched sibling HSCT and unrelatedHSCT.  Blood. 2014. 124(17):2735-43. 

50.  He Y, Wu K, Hu Y, Sheng L, Tie R, Wang B, Huang H*. γδT cell and other immune cells crosstalk in cellular immunity. J Immunol Res. 2014:960252.

51.  Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y, Zheng G, ZhaoY, Ye X, Cai Z, Huang H*. Superiorityof preemptive donor lymphocyte infusion based on minimal residual disease in acuteleukemia patients after allogeneic hematopoietic stem cell transplantation.Transfusion. 2014 Jun;54(6):1493-500.

52.  Tie R, Zhang T, FuH, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H*. Association betweenDNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: asystematic review and meta-analysis. PLoS One. 2014 Jun 17;9(6):e93353.

53.  He J, Yang L, Han X, Zheng G, Zheng W,Wei G, Wu W, Ye X, Shi J, Xie W, Li L, Zhang J, Huang W, Zhao Y, Huang H, Zhang X, Fu J, Cai Z.The choice of regimens based on bortezomib for patients with newly diagnosedmultiple myeloma. PLoS One. 2014 Jun 11;9(6):e99174.

54.  ZiFM, He JS, Li Y, Wu C, Wu WJ, Yang Y, Wang LJ, He DH, Yang L, Zhao Y, Zheng GF,Han XY, Huang H, Yi Q, Cai Z.Fibroblast activation protein protects bortezomib-induced apoptosis in multiplemyeloma cells through β-catenin signaling pathway. Cancer Biol Ther. 2014 Jul21;15(10).

55.  Chen WL, Wang JH, Zhao AH, Xu X,Wang YH, Chen TL, Li JM, Mi JQ, Zhu YM, Liu YF, Wang YY, Jin J, Huang H, Wu DP, Li Y, Yan XJ,Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Chen Z, Chen SJ, Jia W. A distinctglucose metabolism signature of acute myeloid leukemia with prognostic value.Blood. 2014 Sep 4;124(10):1645-54

56.  Wu D, Shao K, Sun J, Zhu F, Ye B, Liu T,Shen Y, Huang H, Zhou Y.Matrine cooperates with all-trans retinoic acid on differentiation induction ofall-trans retinoic acid-resistant acute promyelocytic leukemia Cells (NB4-LR1):possible mechanisms. Planta Med. 2014 Mar;80(5):399-408.

57.  Hu J, Lei Y, Wong WK, Liu S, Lee KC, HeX, You W, Zhou R, Guo JT, Chen X, Peng X, Sun H, Huang H, Zhao H, Feng B. Direct activation of human andmouse Oct4 genes using engineered TALE and Cas9 transcription factors. NucleicAcids Res. 2014 Apr;42(7):4375-90.

58.  Wang X, Wang Y, Huang H, Chen B, Chen X, Hu J,Chang T, Lin RJ, Yee JK. Precise gene modification mediated by TALEN andsingle-stranded oligodeoxynucleotides in human cells. PLoS One. 2014 Apr1;9(4):e93575.

59.  ZhangY, Hu K, Hu Y, Liu L, Wang B, Huang H*.Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect ofgenotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation.Ann Hematol. 2014 Sep;93(9):1499-508.

60.  ZhaoY, Luo Y, Shi J, Cai Z, Huang H*.Second-generation tyrosine kinase inhibitors combined with stem celltransplantation in patients with imatinib-refractory chronic myeloid leukemia.Am J Med Sci. 2014 Jun;347(6):439-45.

61.  Wang Y, Zhao Y, Liu L, Zhang L,Xiao H, Wu K, Xu Y, Hu Y, Fu H, Cao W, Luo Y, Huang H*. Inhibitory effects of imatinib mesylate on humanepidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8.

62.  JiangY, Hu K, Xie W, Zheng G, Sun J, Zheng Y, HuangH*. Hyperthyroidism with  concurrentFMS-like tyrosine kinase 3-internal tandem duplication- positive acute  promyelocytic leukemia: A case report andreview of the literature. Oncol Lett. 2014 Feb;7(2):419-422.

63.  Wu K, Zhao Y, He Y, Wang B, Du K, Fu S, Hu K, Zhang L,Liu L, Hu Y, Wang Y,  Huang H*. Rapamycin interacts synergistically withidarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymalstem cell simulated drug-resistant microenvironment via Akt/mammalian target ofrapamycin and extracellular signal-related kinase signaling pathways.LeukLymphoma.55(3):668-676. 2014.

64.  WuK, Wang Y, He Y, Hu Y, Fu H, Sheng L, Wang B, Fu S,  Huang H*.Dasatinib promotes the potential of proliferation and antitumor responses ofhuman γδT cells in a long-term induction ex vivo environment.Leukemia. 28(1):206-210. 2014.

65.  Gu Y, Hu Y, Hu K, Liao W, Zheng F, Yu X, Huang H*. Rapamycin together with TGF-β1, IL-2 and IL-15 inducesthe generation of functional regulatory γδT cells from human peripheral bloodmononuclear cells. J Immunol Methods. 402(1-2):82-87. 2014.

66.  Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W,Ye X, Yu X, Cai Z, Lin M, Huang H*. Donor TLR9 genetagSNPs influencesusceptibility to aGVHD and CMV reactivation in the allo-HSCT setting withoutpolymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplant. 49(2):241-247.2014.

67.  SunJ, Fu S, Zhong W, Huang H*. PML overexpression inhibitsproliferation and promotes the osteogenic differentiation of human mesenchymalstem cells. Oncol Rep. 30(6):2785-94.2013.

68.  JiangY, Xie W, Hu K, Sun J, Zhu X, Huang H*. An aggressive form of non-Hodgkin'slymphoma with pleural and abdominal chylous effusions: A case report and reviewof the literature. Oncol Lett. 6(4):1120-1122. 2013.

69.  ZhuX, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, LinM, Cai Z, Huang H*.Combination of low-dose mycophenolatemofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelateddonor allogeneic stem cell transplantation. Leuk Res . 37(9): 1046-51. 2013.

70.  Sheng L, Fu S, Hu Y, Fu H, Huang H*. Rapid mobilization of fully functional natural killercells into blood by AMD3100. Transfusion. 53(9):2108-1010. 2013.

71.  Hu Y, Cui Q, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Fu H, LiuL, Fu S, Yu X,  Huang H*.Decitabine facilitates the generationand immunosuppressive function of regulatory gammadeltaT cells derived fromhuman peripheral blood mononuclear cells. Leukemia. 27(7): 1580-1585. 2013.

72.  XieW, Zhou D, Hu K, Xiao X, Huang W, He J, Shi J, Luo Y, Zhang J, Lin M, CaiZ, Huang H, Ye X*. Clinical analysis andprognostic significance of hepatitis B virus infections for diffuse largeB-cell lymphoma with or without rituximab therapy. Exp Ther Med. 6(1):109-114.2013.

73.  ZhaoY, Huang H, Wei G*. Novel agents and biomarkers for acute lymphoid leukemia. JHematol Oncol. 6:40. 2013.

74.  Zhang L, Zheng W, Wang Y, Wang Y, Huang H*. Human bonemarrow mesenchymal stem cells support the derivation and propagation of humaninduced pluripotent stem cells in culture. Cell Reprogram. 15(3):216-223. 2013.

75.  Zhou D, Xie W,Hu K, Huang W, Wei G, He J, Shi J, Luo Y, Li L, Zhu J, Zhang J, Lin M, Ye X,Cai Z, Huang H*. Prognostic valuesof various clinical factors and genetic subtypes for diffuse large B-celllymphoma patients: a retrospective analysis of 227 cases. Asian Pac J CancerPrev. 14(2):929-34. 2013.

76.  Du K, Hu Y, Wu K, HuangH*. Long-term outcomes of antithymocyte globulin in patients withhematological malignancies undergoing myeloablative allogeneic hematopoieticcell transplantation: a systematic review and meta-analysis. Clin Transplant.27(2):E91-E100. 2013.

77.  Zheng W, Wang Y, Chang T, Huang H*. and Yee JK*. Significant differencesin genotoxicity induced by retrovirus integration in human T cells and inducedpluripotent stem cells. Gene. 519(1):142-9. 2013.

78.  Xie W, Hu K,Xu F, Zhou D, He J, Shi J, Luo Y, Zhu J, Zhang J, Lin M, Ye X, HuangH, Cai Z*. Clinical analysis and prognostic significance oflymphoma-associated hemophagocytosis in peripheral T cell lymphoma. AnnHematol. 92(4): 481-486. 2013.

79.  ShiJ, Meng X, Luo Y, Tan Y, Zhu X, Zheng G, He J, Zheng WY Xie W, Li L, Ye X,Zhang J, Cai Z, Lin M, Huang H*. Clinical characteristics and outcome of isolated extramedullary relapsein acute leukemia after allogeneic stem cell transplantation: a single-centeranalysis. Leuk Res. 37(4):372-7.2013.

80.  He J, Zhu L, Ye X, Li L, Zhu J, Zhang J, Xie W, Shi J, Zheng W, Wei G, Sun J, CaiZ, HuangH*. Clinical Characteristics and Prognosis of 23 Patients With Nonleukemic Myeloid Sarcoma.Am J Med Sci. 2014 Jun;347(6):434-8.

81.  WangC, Xiao H, Ma J, Zhu Y, Yu J, Sun L, Sun H, Liu Y, Jin C, Huang H*.  The F-box protein beta-TrCP promotesubiquitination of TRF1 and regulates the ALT-associated PML bodies formation inU2OS cells. Biochem Biophys Res Commun.434(4):728-34. 2013.

82.  Xie W, Zhao Y, Cao L, Huang W, Wang Y, Huang H*. Cutaneous blastic plasmacytoid dendritic cellneoplasm occurring after spontaneous remission of acute myeloid leukemia: acase report and review of literature.Med Oncol. 29(4):2417-22. 2012.

83.  Xiao H, Luo Y,Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X,Yu X, Cai Z, Lin M, Huang H*. Genetic variations inT-cell activation and effector pathways modulate alloimmune responses afterallogeneic hematopoietic stem cell transplantation in patients with hematologicmalignancies. Haematologica.97 (12):1804-1812. 2012.

84.  Hu Y, Gu Y,Cui Q, Fu H, Sheng L, Wu K, Liu L, Fu S, Yu X, Huang H*. Phytohemagglutinin -activated human T cells induce lethal graft-versus-host disease incyclophosphamide and anti - CD122 conditioned NOD/SCID mice. Ann Hematol . 91(11): 1803-1822. 2012.

85.  Zhu Y, Wang C,Lan J, Yu J, Jin C. & Huang H*.Phosphorylation of Tara by Plk1 is essential for faithful chromosomesegregation in mitosis. Exp Cell Res. 318 (18), 2344-2352. 2012.

86.  Liu L, Hu K, Wang B, HuangH*. Yu, Q. Mobilizationof endogenous stem cells: A new strategy for bone healing. Bone. 51 (3): 633-634. 2012. (IF: 3.823)

87.  Wu W, Cao L, Li Y, Yu X, Huang H, He J*. Primary splenic diffuse large B-cell lymphoma in a patient withthymus Rosai-Dorfman disease. Am J Med Sci. 344(2):155-9. 2012.

88.  Wu K, Luo Y, Liu L, Zhao Y, Hu Y, Tan Y,Lai X , Huang H*. Twinpregnancy and childbirth after reduced-intensity conditioning allogeneichaematopoietic stem cell transplantation combined with imatinib mesylate forchronic myeloid leukaemia: case report and literature review. J Int Med Res .40:2409-15. 2012.

89.  Wang T, Huang H,CHTzeng, Wang P, Wu T, Sun J, Tang J, Hu J, Lin S, Kao R*. Impact of donorcharacteristics and HLA matching on survival of chinese patients withhematologic malignancies undergoing unrelated hematopoietic stem celltransplantation. Biol Blood Marrow Transplant .18:1939-44. 2012.

90.  Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J*. Multicenter, randomized,open-label study comparing the efficacy and safety of micafungin versusitraconazole for prophylaxis of invasive fungal infections in patientsundergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant18:1509-16. 2012.

91.  Xu Y, Liu L, Zhang L, Fu S, Hu Y, Wang Y, Fu H, Wu K, Xiao H,Liu S, Yu X, Zheng W, Feng B, Huang H*.Efficient commitment tofunctional CD34+ progenitor cells from human bone marrow mesenchymalstem-cell-derived induced pluripotent stem cells. PLoS One 7(4): e34321. 2012.

92.  ZhangL, Wang Y, Huang H*. Defibrotidefor the prevention of hepatic veno-occlusive disease after hematopoietic stemcell transplantation: a systematic review.Clin Transplant.26 (4): 511-519. 2012.

93.  SunJ, Wang Z, Luo Y, Tan Y, David S.Allan, HuangH*.Prolongedsurvival with imatinib mesylate combined with chemotherapy and allogeneic stemcell transplantation in de novo Ph+ acute myeloid leukemia. Acta Haematol.127:143-148. 2012.

94.  XuY, Liu L, Zhang L, Fu S, Li R, Hu K and HuangH*.Efficientgeneration of induced pluripotent stem cells from human bone marrow mesenchymalstem cells. Folia Biol (Praha) . 58(6):221-30. 2012.

95.  Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, XieW, Li L, Ye X, Yu X, Lin M, Cai Z,Huang H*. Geneticvariations in the mycophenolate mofetil target enzyme are associated with acuteGVHD risk after related and unrelated hematopoietic cell transplantation. BiolBlood Marrow Transplant. 18(2): 273-279. 2012.

96.  HuY, LuoY, Tan Y, Shi J, Sheng L, Fu H, Liu L, Xu Y, Wu K, Xiao H, Zhang L, Yu X,Cai Z, HuangH*. Donor bone marrow-derived stem cells contribute tooral squamous cell carcinoma transformation in a recipient after hematopoieticstem cell transplantation. Stem Cells Dev. 21: 177-180. 2012.

97.  ChangT, Zheng W, Tsark W, Bates S, Huang H, Lin R, Yee JK*.  Phenotypicrescue of Induced pluripotent stem cell-derived motoneurons of a spinalmuscular atrophy patient. Stem Cells. 29: 2090-2093. 2011.

98.  Wei G, Ni W, Chiao J, Cai Z, Huang H, Liu D*. Ameta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for thetreatment of 1029 patients with acute myeloid leukemia and myelodysplasticsyndrome. J Hematol Oncol, 4: 46. 2011.

99.  Liu L, Wang Y, Wu K, Fu S, Zhang L, Xu Y, Huang H*. The tyrosine kinaseinhibitor nilotinib inhibits proliferation and osteoblast differentiation ofhuman mesenchymal stromal cells. Bone. 49(5):1117-1118. 2011.

100. Liu L, Yu Q, Lin J, Lai X, Cao W, Du K, Wang Y, Wu K, Hu Y,Zhang L, Xiao H, Duan Y, Huang H*. Hypoxia-induciblefactor-1α is essential for hypoxia-induced mesenchymal stem cell mobilizationinto the peripheral blood. Stem Cells Dev. 20(11):1961-71. 2011.

101. LuoY, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M,Huang H*. Imatinib combined with myeloablativeallogeneic hematopoietic stem cell transplantation for advanced phases ofchronic myeloid leukemia. Leu Res. 35: 1307-1311. 2011.

102. Zhao Y, Tan Y, Wu G, Liu L, Wang Y, Luo Y, Shi J, Huang H*.Berbamine overcomes imatinib-induced neutropenia and permits cytogeneticresponses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol. 94:156-162. 2011.

103. Hu Y, Cui Q, Liang B,HuangH* Relapsing hematologic malignancies afterhaploidentical hematopoietic stem cell transplantation. Biol Blood MarrowTransplant. 17(8): 1099-1111.2011.

104. Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W,Zhang L, Wang Y, Liu L, Wu K, Yu X, Cai Z, Lin M, Ye X, Huang H*.First report of multiple CEBPA mutationscontributing to donor origin of leukemia relapse after allogeneic hematopoieticstem cell transplantation. Blood. 117(19): 5257-5260. 2011.

105. Tan Y, Fu H, LuoY, Shi J, Ye X, ZhengY, Xiao H, Hu Y, Huang H*..Haploidentical Allogeneic Haematopoietic Stem Cell Transplantation asSalvage Therapy for Engraftment Failure after Unrelated and Autologous StemCell Transplantation: a Case Report and Review of the Literature. J IntMed Res. 39: 950-959. 2011.

106. XiaoH, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng W, Zheng G,Han X, Jin L, Zhang L, Wang Y, Yu X, Cai Z, Lin M, Ye X, HuangH*.Immunosuppressive cytokine gene polymorphisms and outcome after related andunrelated hematopoietic cell transplantation in Chinese population. Biol BloodMarrow Transplant. 17: 542-549. 2011.

107. XiaoH, Lai X, LuoY, Shi J, Tan Y, He J, Xie W, Li L, Zhu X, Zhu J, Sun J, Wei G,Jin L,Liu L,Wu K,Yu X, Cai Z, Lin M, Ye X, Huang H*. Relationship between TNFA, TNFB andTNFRII gene polymorphisms and outcome after unrelated hematopoietic celltransplantation in Chinese population. Bone Marrow Transplant. 46: 400-407.2011.

108. MouH, Lin M, Huang H, Cai Z*.Transforming growth factor-beta1 modulates lipopolysaccharide-inducedcytokine/chemokine production and inhibits nuclear factor-kappaB, extracellularsignal-regulated kinases and p38 activation in dendritic cells in mice.Transplant Proc. 2011. 43(5):2049-2052.

109. WangC, Yu J, Yuan K, Lan J, Jin C*, Huang H*.  Plk1-mediated phosphorylation of PinX1regulates its stability. Eur J Cell Biol. 89(10): 748-756. 2010.

110. Hu Y, Cui Q, Liang B, HuangH*. Donor-derivedsolid malignancies after hematopoietic stem cell transplantation. Onkologie.33(4):195-200. 2010.

111. Wu G,Zhao Y, Lai X, Luo Y, Tan Y, Shi J, Li L, Zheng W, Zhang J, Hu X, Jin A, He J,Xie W, Ye X, Cai Z, Lin M, Huang H*. The beneficialimpact of missing KIR ligands and absence of donor KIR2DS3 gene on outcomefollowing unrelated hematopoietic SCT for myeloid leukemia in the Chinesepopulation. Bone Marrow Transplant. 45: 1514-1521. 2010.

112. ZhengW, Guan M, Zhu L, Cai Z, Chung V, Huang H*, YenY. Bortezomib therapeutic effect is associated with expression and mutation ofFGFR3 in human lymphoma cells. Anticancer Res. 30(6): 1921-1930. 2010.

113. Dong-WookKim*, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, Huang H, Ian Irving, Saengsuree Jootar, Hyun-GyungGoh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman,Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, JianminWang, Raymond Wong. Chronic myeloid leukemia in the Asia-Pacific region:current practice, challenges and opportunities in the targeted therapy era.Leuk Res. 34(11): 1459-1471. 2010.

114. Yu J,Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C*, HuangH*. PML3 interacts with TRF1 and is essential forALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 291(2): 177-186.2010.

115. Wu G,Zhao Y, Lai X, Yang K, Zhu F, Zhang W, Wang W, Luo Y, Tan Y, Wang Y, Cao W, Huang H*.Distribution of killer-cell immunoglobulin-like receptor genes in Easternmainland Chinese Han and Taiwanese Han populations. Tissue Antigens. 74(6):499-507. 2009.

116. Wu Q,Hu H, Lan J, Emenari C, Wang Z, Chang K, HuangH, Yao X*. PML3 Orchestrates the Nuclear Dynamics andFunction of TIP60. J Biol Chem. 284(13):8747-8759. 2009.

117. LuoY, Lai X, Tan Y, Shi J, Zhao Y, Han X, Zheng G, Zhu X, Sun J, Zheng Y, Wu G, HeJ, Chen S, Jin A, Xie W, Ye X, Cai Z, Lin M, HuangH*.Reduced-intensity allogeneic transplantation combined with imatinib mesylatefor chronic myeloid leukemia in first chronic phase. Leukemia. 23(6):1171-1174.2009.

118. ZhaoY, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z,Lin M, Huang H*. Efficacy and Prognosis of Chronic Myeloid Leukemia TreatedWith Imatinib Mesylate in a Chinese Population. Int J Hematol.89(4):445-451. 2009.

119. ZhaoY, Wu G, Wu K, Liu L, Cao W, Yu X, Luo Y, Shi J, Tan Y, Huang H*.  Simultaneousoccurrence of variant Philadelphia translocations and ABL mutations in twopatients with chronic myeloid leukemia. Leuk Res. 33(7):e85-87. 2009.

120. ZhengW, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X,Lin M, Huang H, CaiZ*. Bortezomib in combination withdexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma:a Chinese experience. Leuk Res. 33(12):1615-1618. 2009.

121. QiuL, He J*, Ye X, Xie W, Shi J, Zheng W, Sun J, Zhu X, Cai Z, Huang H, Lin M. Invasive pulmonary fungalinfection accompanied by severe hemoptysis in patients with hematologicdiseases: a report of nine cases. Int J Hematol. 90(1):108-112. 2009.

122. ShiJ, Cai Z*, Huang H, YeX, He J, Xie W, Zhang J, Zhou X, Luo Y, Lin Y, Li L, Zheng W, Wei G, Lin M.Role of CT-guided percutaneous lung biopsy in diagnosis of pulmonary fungalinfection in patients with hematologic diseases. Int J Hematol. 89(5):624-627.2009.

123. Yu J,Lan J, Zhu Y, Li X, Lai X, Xue Y, Jin C*, HuangH*. The E3 ubiquitin ligase HECTD3 regulates ubiquitination anddegradation of Tara. Biochem Biophys ResCommun. 367(4):805-812. Mar 2008. 

124. ZhaoYM, Li JY, Lan JP, Lai XY, Luo Y, Sun J, Yu J, Zhu YY, Zeng FF, Zhou Q, Huang H*. Cell cycle dependenttelomere regulation by telomerase in human bone marrow mesenchymal stem cells.Biochem Biophys Res Commun. 369(4): 1114-1119. May 2008. 

125. ZhaoYM, Zhou Q, Xu Y, Lai XY, Huang H*.Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkatby cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin. 29(4):481-488. Apr 2008.

126. ChengZ, Ke Y, Ding X, Wang F, Wang H, Wang W, Ahmed K, Liu Z, Xu Y, Aikhionbare F,Yan H, Liu J, Xue Y, Yu J, Powell M, Liang S, Wu Q, Reddy SE, Hu R, Huang H, Jin C, Yao X*.Functional characterization of TIP60 sumoylation in UV-irradiated DNA damageresponse. Oncogene. 27(7): 931-941. Feb 2008.

127. LuoY, Zhang A, Huang H*, ZhengS. Haemolytic uraemic syndrome after living-donor liver transplantation:is small-for-size graft a potential riskfactor J Int Med Res. 36(3):599-604. May-Jun 2008.

128. Li X,Lan J, Zhu Y, Yu J, Dou Z, Huang H*.Expression, purification, and characterization of Tara,a novel telomere repeat-binding factor 1 (TRF1)-binding protein. Protein ExprPurif. 55(1):84-92. Sep 2007.

129. SunJ, Huang H*, Zhu Y, Lan J, LiJ, Lai X, Yu J. The expression of telomeric proteins and their probableregulation of telomerase during the differentiation of all-trans-retinoicacid-responsive and -resistant acute promyelocytic leukemia cells. Int J Hematol. 82(3):215-222. Oct 2005.

130. Fu C,Ahmed K, Ding H, Ding X, Lan J, Yang Z, Miao Y, Zhu Y, Shi Y, Zhu J, Huang H*, Yao X*. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.Oncogene. 24(35): 5401-5413. Aug 2005.